Advaxia Biologics

Executive Summary

Advaxia Biologics is a Milan-based contract development and manufacturing organization (CDMO) specializing in adenovirus-based biologics and vaccines. Founded in 2018, the company offers fully integrated services from process development to cGMP manufacturing for viral vector products. With a proven track record of collaborating with major pharmaceutical companies on vaccines for Ebola and COVID-19, Advaxia is well-positioned to capitalize on the growing demand for viral vector manufacturing in immunology and oncology. Its expertise in adenovirus platforms, combined with a commitment to quality and scalability, makes it a key partner for biotech and pharma clients seeking reliable CDMO services. As the landscape for gene-based therapies expands, Advaxia's specialized capabilities and strategic location in Europe provide a competitive edge.

Upcoming Catalysts (preview)

• Q3 2026New major pharma contract for oncology vaccine70% success
• Q4 2026Expansion of cGMP manufacturing capacity80% success
• 2027Strategic partnership for rare disease gene therapy50% success